AARTIDRUGS Stock Overview
Through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Aarti Drugs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹411.50 |
| 52 Week High | ₹635.00 |
| 52 Week Low | ₹370.00 |
| Beta | 0.83 |
| 1 Month Change | -2.23% |
| 3 Month Change | -10.62% |
| 1 Year Change | -22.35% |
| 3 Year Change | -17.44% |
| 5 Year Change | 144.50% |
| Change since IPO | 3,754.80% |
Recent News & Updates
Recent updates
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Sep 20
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet
Sep 05Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?
May 04Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models
Feb 01Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00
Jan 30Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think
May 17These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well
Nov 22We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet
Aug 28Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching
Aug 19Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value
May 17Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock
Apr 04Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?
Mar 17Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?
Feb 17Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio
Feb 04
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?
Jan 22Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth
Jan 07If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late
Dec 23Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly
Dec 08Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 23How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?
Nov 08Shareholder Returns
| AARTIDRUGS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.2% | -7.5% | -5.6% |
| 1Y | -22.4% | 9.0% | -0.9% |
Return vs Industry: AARTIDRUGS underperformed the Indian Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: AARTIDRUGS underperformed the Indian Market which returned -0.9% over the past year.
Price Volatility
| AARTIDRUGS volatility | |
|---|---|
| AARTIDRUGS Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: AARTIDRUGS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AARTIDRUGS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,064 | Prakash Patil | www.aartidrugs.co.in |
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate.
Aarti Drugs Limited Fundamentals Summary
| AARTIDRUGS fundamental statistics | |
|---|---|
| Market cap | ₹37.77b |
| Earnings (TTM) | ₹1.53b |
| Revenue (TTM) | ₹23.30b |
24.8x
P/E Ratio1.6x
P/S RatioIs AARTIDRUGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AARTIDRUGS income statement (TTM) | |
|---|---|
| Revenue | ₹23.30b |
| Cost of Revenue | ₹15.22b |
| Gross Profit | ₹8.09b |
| Other Expenses | ₹6.56b |
| Earnings | ₹1.53b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.60 |
| Gross Margin | 34.70% |
| Net Profit Margin | 6.55% |
| Debt/Equity Ratio | 46.2% |
How did AARTIDRUGS perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield6%
Payout RatioDoes AARTIDRUGS pay a reliable dividends?
See AARTIDRUGS dividend history and benchmarks| Aarti Drugs dividend dates | |
|---|---|
| Ex Dividend Date | Feb 04 2025 |
| Dividend Pay Date | Feb 28 2025 |
| Days until Ex dividend | 13 days |
| Days until Dividend pay date | 11 days |
Does AARTIDRUGS pay a reliable dividends?
See AARTIDRUGS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 11:57 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aarti Drugs Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rashmi Sancheti Shetty | CGS International |
| Rashmi Sancheti Shetty | Dolat Capital Market Pvt. Ltd. |
| Rishabh Kale | Indsec Securities & Finance Ltd. |